Company intelligence / Profile preview

Zevacor Molecular

Noblesville, Indiana, United Statescuriumpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Prior to its acquisition by Curium in March 2020, Zevacor Molecular was a leading U.S. producer of Strontium‑82 used to manufacture Rubidium‑82 generators for cardiac PET imaging—the most frequently used agent for this purpose in the U.S. The company also developed and distributed a range of radioisotopes for clinical and research use. No therapeutic clinical results as it focused on diagnostic radiopharmaceuticals.

Therapeutic areas: OtherCardiovascular
Modalities: RadiopharmaceuticalSmall molecule
Industry: Medical Imaging

Drug pipeline

1 asset

rubidium-82

Commercial

Indications: Cardiac PET imaging

Partnerships

DMH Worldwide (previous owner prior to Curium acquisition)

Beyond the preview

Go deeper on Zevacor Molecular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zevacor Molecular.

Explore the full profile